Question 1

Does Citadel Advisors own NXTC stock?

Accepted Answer

No. Citadel Advisors exited its NXTC (NextCure) position in Q3 2025. Its Q2 2025 13F listed 58,845 shares worth $27,069.

Question 2

How many shares of NXTC does Citadel Advisors own?

Accepted Answer

None since Q3 2025, when Citadel Advisors exited the position. Its Q2 2025 13F listed 58,845 shares worth $27,069.

Question 3

What is Citadel Advisors' NXTC position worth?

Accepted Answer

Citadel Advisors' NXTC position was worth $27,069 in its Q2 2025 13F, before the exit in Q3 2025.

Question 4

Is Citadel Advisors buying or selling NXTC?

Accepted Answer

In Q3 2025, Citadel Advisors exited its entire NXTC position.

Question 5

When did Citadel Advisors first buy NXTC?

Accepted Answer

Citadel Advisors first reported NXTC in its Q2 2019 13F and listed it in 25 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2025-Q3 Latest	Exited	0	-100.0%	$0	0.0%	$5.86	0
2025-Q2	Decreased	58,845	-35.1%	$27,069	0.0%	$5.52	0
2025-Q1	Increased	90,643	+15.2%	$43,536	0.0%	$5.76	16
2024-Q4	Increased	78,678	+40.6%	$60,661	0.0%	$9.25	19
2024-Q3	Decreased	55,954	-80.6%	$76,657	0.0%	$16.44	0